<html>
<head>
<title>Form 8-K
</title>
</head>
<body>




<hr size=3 noshade>

<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br></b></font>
<font face="Times New Roman, Times, Serif" size=2>Washington, DC 20549</font>
</p>

<hr width=25% noshade>

<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>FORM 8-K<br>
<br></b></font></p>
<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>CURRENT REPORT</b></font><br><font face="Times New Roman, Times, Serif" size=2><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934<br></b></font></p>
<p align=center>
<font face="Times New Roman, Times, Serif" size=2>Date of Report&nbsp;&nbsp;(Date of earliest event reported):&nbsp;&nbsp;&nbsp;&nbsp;August 3, 2005</font><br></p>
<hr width=25% noshade>
<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>MILLENNIUM PHARMACEUTICALS, INC.</b></font><br><font face="Times New Roman, Times, Serif" size=2>(Exact name of registrant as specified in its charter)</font></p>
<table width=100% border=0 cellpadding=0 cellspacing=0 align=center>

<tr>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>Delaware</b></font></td>
<td width=34% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>0-28494</b></font></td>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>04-3177038</b></font></td>
</tr>
<tr>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(State or other jurisdiction<br>of incorporation)</font></td>
<td width=34% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(Commission file number)</font></td>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(IRS&nbsp;Employer<br>Identification&nbsp;No.)</font></td>
</tr>




</table>


<p align=center><font face="Times New Roman, Times, Serif" size=2><b>40 Landsdowne Street<br>Cambridge, Massachusetts 02139</b><br>
(Address of principal executive offices)&nbsp;(zip code)</font></p>

<p align=center><font face="Times New Roman, Times, Serif" size=2><b>(617)&nbsp;&nbsp;679-7000<br></b>
(Registrant's telephone number, including area code)</font></p>

<p align=center><font face="Times New Roman, Times, Serif" size=2><b>Not applicable<br></b>
(Former name or former address if changed since last report)</font></p>

<p align=left><font face="Times New Roman, Times, Serif" size=2>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></p>

<table width=100% border=0 cellpadding=0 cellspacing=0>

<tr>
<td align=right valign=top width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top width=1%><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top width=2%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=top width=94%><font face="Times New Roman, Times, Serif" size=2>Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>

</table>


<hr size=3 noshade width=100%>


<p align=left><font face="Times New Roman, Times, Serif" size=2><b>Item&nbsp;&nbsp;&nbsp;&nbsp;1.01 Entry into a Material Definitive Agreement.
</b></font></p>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On
August 3, 2005, Millennium Pharmaceuticals, Inc. (the &#147;Company&#148;) entered into a
consulting agreement with Mark J. Levin, a member of the Company&#146;s Board of Directors
and former Chief Executive Officer of the Company, to provide services to the Company on
an as needed basis, expected to be approximately one day per week initially, to support
Deborah Dunsire in her new role as the Company&#146;s Chief Executive Officer. The Company will pay Mr. Levin
an initial monthly retainer of $16,000 through December 31, 2005. The term of the
agreement will begin effective as of August 1, 2005, will end on December 31, 2005 and
will be renewable quarterly thereafter as mutually agreed. After the initial term of the
agreement, any renewal of the term, determination of services to be provided by Mr. Levin
and compensation paid to him during any such renewal term will be reviewed by
the Chairman of the Board and approved by the Board of Directors.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On
August 3, 2005, the Company&#146;s Board of Directors changed the title of its Lead
Outside Director to Vice Chairman of the Board and modified the responsibilities for the
position. Grant Heidrich, III will continue to serve in this role as the Vice Chairman of
the Board. The compensation of the Vice Chairman of the Board will be the same as it was
for the Lead Outside Director including a $10,000 additional annual retainer and an
additional annual stock option grant of 5,000 shares.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On
August 3, 2005, the Board approved the following incremental compensation to be paid to
the non-employee Chairman of the Board in addition to the compensation paid to all
non-employee directors: </FONT></P>

<table width=100% border=0 cellpadding=0 cellspacing=0>

<tr>
<td align=right valign=top width=9%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top width=1%><font face="Times New Roman, Times, Serif" size=2>&#149;</font></td>
<td align=right valign=top width=2%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=top width=88%><font face="Times New Roman, Times, Serif" size=2>A $20,000 additional annual retainer for the non-employee Chairman of the Board prorated for any
         portion of a year served; and</font></td>
</tr>

<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#149;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>An additional annual stock option grant for 10,000 shares to the non-employee Chairman to
be granted in 2005 on August 3, 2005, with monthly vesting over one year, and in the
following years at the same time and on the same terms as the annual non-employee director
stock option grants.</font></td>
</tr>


</table>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On
August 3, 2005, the Company&#146;s Board of Directors also approved a one-time payment of
$20,000 to each of the following directors, Grant Heidrich, Raju Kucherlapati, Norman
Selby and Ken Weg, for their participation over the past two years in the group
responsible for the search for the Company&#146;s new Chief Executive Officer. </FONT></P>


<p align=center><font face="Times New Roman, Times, Serif" size=2>2</font></p>
<hr size=3 noshade>







<p align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2><b><a name="sig">SIGNATURE</a></b></font></p>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.</font></p>




<table border=0 cellpadding=0 cellspacing=0>
<tr valign=bottom>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td colspan=2><font face="Times New Roman, Times, Serif" size=2>MILLENNIUM PHARMACEUTICALS, INC.<br>(Registrant)<br><br></font></td>
</tr>
<tr valign=bottom>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: August 5, 2005&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>By&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>/s/&nbsp;&nbsp;MARSHA H. FANUCCI</font></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2></font><hr noshade></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>Marsha H. Fanucci</font></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>Senior Vice President and Chief Financial Officer</font></td>
</tr>
</table>




<p align=center><font face="Times New Roman, Times, Serif" size=2>3</font></p>
<hr noshade size=3>






</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "fm8k08032005.htm", "description": "FORM 8-K", "secsgml_size_bytes": 13004}]
{"company-data": {"conformed-name": "MILLENNIUM PHARMACEUTICALS INC", "cik": "0001002637", "assigned-sic": "2834", "irs-number": "043177038", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-28494", "film-number": "051000950"}, "business-address": {"street1": "40 LANDSDOWNE STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02139", "phone": "6176797000"}, "mail-address": {"street1": "40 LANDSDOWNE STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02139"}}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report  (Date of earliest event reported):    August 3, 2005
MILLENNIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
0-28494
04-3177038
(State or other jurisdiction
of incorporation)
(Commission file number)
(IRS Employer
Identification No.)
40 Landsdowne Street
Cambridge, Massachusetts 02139
(Address of principal executive offices) (zip code)
(617)  679-7000
(Registrant's telephone number, including area code)
Not applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item    1.01 Entry into a Material Definitive Agreement.
On
August 3, 2005, Millennium Pharmaceuticals, Inc. (the "Company") entered into a
consulting agreement with Mark J. Levin, a member of the Company's Board of Directors
and former Chief Executive Officer of the Company, to provide services to the Company on
an as needed basis, expected to be approximately one day per week initially, to support
Deborah Dunsire in her new role as the Company's Chief Executive Officer. The Company will pay Mr. Levin
an initial monthly retainer of $16,000 through December 31, 2005. The term of the
agreement will begin effective as of August 1, 2005, will end on December 31, 2005 and
will be renewable quarterly thereafter as mutually agreed. After the initial term of the
agreement, any renewal of the term, determination of services to be provided by Mr. Levin
and compensation paid to him during any such renewal term will be reviewed by
the Chairman of the Board and approved by the Board of Directors.
On
August 3, 2005, the Company's Board of Directors changed the title of its Lead
Outside Director to Vice Chairman of the Board and modified the responsibilities for the
position. Grant Heidrich, III will continue to serve in this role as the Vice Chairman of
the Board. The compensation of the Vice Chairman of the Board will be the same as it was
for the Lead Outside Director including a $10,000 additional annual retainer and an
additional annual stock option grant of 5,000 shares.
On
August 3, 2005, the Board approved the following incremental compensation to be paid to
the non-employee Chairman of the Board in addition to the compensation paid to all
non-employee directors:
•
A $20,000 additional annual retainer for the non-employee Chairman of the Board prorated for any
         portion of a year served; and
•
An additional annual stock option grant for 10,000 shares to the non-employee Chairman to
be granted in 2005 on August 3, 2005, with monthly vesting over one year, and in the
following years at the same time and on the same terms as the annual non-employee director
stock option grants.
On
August 3, 2005, the Company's Board of Directors also approved a one-time payment of
$20,000 to each of the following directors, Grant Heidrich, Raju Kucherlapati, Norman
Selby and Ken Weg, for their participation over the past two years in the group
responsible for the search for the Company's new Chief Executive Officer.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
MILLENNIUM PHARMACEUTICALS, INC.
(Registrant)
Date: August 5, 2005
By
/s/  MARSHA H. FANUCCI
Marsha H. Fanucci
Senior Vice President and Chief Financial Officer
3